Elsevier

Clinical Colorectal Cancer

Volume 4, Issue 4, November 2004, Pages 262-267
Clinical Colorectal Cancer

Original Contribution
Expression of Vascular Endothelial Growth Factor and HER2/neu in Stage II Colon Cancer and Correlation with Survival

https://doi.org/10.3816/CCC.2004.n.025Get rights and content

Abstract

Monoclonal antibody–directed therapy has been used as an effective treatment for some cancers that overexpress HER2/neu and vascular endothelial growth factor (VEGF). Overexpression of the HER2/neu oncogene and VEGF has been reported to occur in adenocarcinomas of the colon. Assessing whether HER2/neu and VEGF overexpression could serve as prognostic indicators for stage II colon cancer may provide insight into optimal treatment following surgery. Demographic and tumor characteristics from 109 patients diagnosed with stage II colon cancer between 1991 and 1996 were assessed for HER2/neu and VEGF expression using immunohistochemical staining techniques. Of the 109 cases, 107 (98%) were histologically classified as adenocarcinomas, 105 (96%) were grades 2/3, and 105 (96%) were stage T3. Only 12 cases (11%) exhibited HER2/neu overexpression and 72 cases (66%) exhibited VEGF expression. There was no significant difference in overall survival or in time to recurrence between the groups with and without HER2/neu overexpression. There was a trend toward decreased overall survival with VEGF expression (P = 0.07), but no difference in time to recurrence (P = 0.63). There were 18 patients who received adjuvant chemotherapy, but removal of these patients from the analysis did not change the results. There was no association between HER2/neu and VEGF expression and patient demographics or tumor characteristics, with the exception of VEGF expression and mucinous histology (P < 0.01). Our results do not support an association between HER2/neu or VEGF expression and overall survival or time to recurrence in stage II colon cancer. With further investigation, a significant correlation may be found between VEGF expression and prognosis, and thus direct therapy with a monoclonal antibody.

References (38)

  • S Kapitanovic et al.

    The expression of p185HER-2/neu correlates with the stage of disease and survival in colorectal cancer

    Gastroenterology

    (1997)
  • J Yokota et al.

    Amplification of cerbB-2 proto-oncogenes in human adenocarcinoma in vivo

    Lancet

    (1986)
  • T Tominaga et al.

    Prognostic factors for patients with colon or rectal carcinoma treated with resection only

    Cancer

    (1996)
  • S Cascinu et al.

    Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer

    Clin Cancer Res

    (2000)
  • J D'Emilia et al.

    Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon

    Oncogene

    (1989)
  • GJ Tsioulias et al.

    erbB-2 gene expression in colorectal cancer

    Jpn J Exp Med

    (1990)
  • M Tal et al.

    Sporadic amplification of the HER-2/neu protooncogene in adenocarcinomas of various tissues

    Cancer Res

    (1988)
  • DJ Slamon et al.

    Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

    Science

    (1989)
  • MS Berger et al.

    Correlation of c-erb-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading

    Cancer Res

    (1988)
  • C Wright et al.

    Expression of c-erb-2 oncoprotein: a prognostic indicator in human breast cancer

    Cancer Res

    (1989)
  • S Paik et al.

    Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erb-2 protein overexpression in primary breast cancer

    J Clin Oncol

    (1990)
  • HB Muss et al.

    C-erb-2 expression and response to adjuvant therapy in women with node positive early breast cancer

    N Engl J Med

    (1994)
  • C Wright et al.

    Relationship between c-erb-2 protein product expression and response to endocrine therapy in advanced breast cancer

    Br J Cancer

    (1992)
  • CC Hsieh et al.

    Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of the lung

    Ann Thorac Surg

    (1998)
  • DR Nathanson et al.

    HER-2/neu expression and gene amplification in colon cancer

    Int J Cancer

    (2003)
  • AH Arnaout et al.

    HER-2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies

    J Clin Pathol

    (1992)
  • G Neufeld et al.

    Vascular endothelial growth factor (VEGF) and its receptors

    FASEB J

    (1999)
  • T Tokunaga et al.

    Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor performance prognosis in colon cancer

    Br J Cancer

    (1998)
  • Y Takahashi et al.

    Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer

    Cancer Res

    (1995)
  • Cited by (46)

    • What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?

      2014, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      Oncogenesis may result from destabilization of the equilibrium between proliferative and apoptotic signals, resulting in the overgrowth of cancer cells and the formation of solid tumors [11]. Many CRCs overexpress various growth factors and their respective receptors, including epidermal growth factor (EGF), transforming growth factor (TGF)-α, TGF-β1, platelet-derived growth factor (PDGF), human epidermal growth factor receptor-2 (HER2)/neu, VEGF, and fibroblast growth factor (FGF) [12–16]. Colorectal tumor growth and aggressiveness are modulated by genetic alterations in growth factors and their receptors via amplification and/or mutation in conjunction with multiple alterations in oncogenes and tumor suppressor genes.

    • Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: A potential therapeutic target in colorectal cancer

      2011, Cancer Letters
      Citation Excerpt :

      New therapeutic strategies such as molecular-targeted agents are a high priority for patients with advanced stage disease [1]. A high percentage of CRCs overexpress a number of growth factors and their receptors, including the epidermal growth factor (EGF) receptor, EGF, transforming growth factor (TGF)-α, TGF-β1, platelet-derived growth factor (PDGF), HER2/neu, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) 2, FGF1, FGF receptor (FGFR) 1, and FGFR2 [2–6]. Amplification and/or mutation of these growth factors and growth factor receptors influence CRC cell growth and cell behavior in an autocrine- and/or paracrine-dependent manner.

    View all citing articles on Scopus

    Electronic forwarding or copying is a violation of US and International Copyright Laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cancer Information Group, ISSN #1533-0028, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

    View full text